Calculated prostate cancer volume: The optimal predictor of actual cancer volume and pathologic stage

Urology

Volumn 49, Issue 3, 1997, Pages 385-391

  D'Amico, Anthony V ^a   Chang, Hyunil ^b   Holupka, Edward ^b   Renshaw, Andrew ^b   Desjarden, April ^b   Chen, Minghui ^b   Loughlin, Kevin R ^b   Richie, Jerome P ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; HUMAN; HUMAN TISSUE; IMAGE RECONSTRUCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM;

HUMANS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS;

EID: 0030891004     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00509-2     Document Type: Article

References (23)

1. McNeal JE: Origin and development of carcinoma in the prostate. Cancer 23: 24-34, 1969.
2. Blackwell KI, Bostwick DG, Myers RP, Zincke H, and Oesterling JE: Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. J Urol 151: 1565-1570, 1994.
3. McNeal JE: Cancer volume and site of origin of adenocarcinoma of the prostate: relationship to local and distant spread. Hum Pathol 23: 258-263, 1992.
4. McNeal JE, Kindrachuk RA, Freiha FS, Bostwick DG, Redwine EA, and Stamey TA: Patterns of progression in prostate cancer. Lancet 1: 60-63, 1986.
5. McNeal JE, Villers AA, Redwine EA, Freiha FS, and Stamey TA: Capsular penetration in prostate cancer: significance for natural history and treatment. Am J Surg Pathol 14: 240-247, 1990.
6. McNeal JE, Villers AA, Redwine EA, Freiha FS, and Stamey TA: Histologic differentiation, cancer volume in pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 66: 1225-1233, 1990.
7. Stamey TA, McNeal JE, Freiha FS, and Redwine EA: Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 139: 1235-1241, 1988.
8. Villers AA, McNeal JE, Redwine EA, Freiha FS, and Stamey TA: Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J Urol 143: 1183-1187, 1990.
9. Stamey TA, Yang N, Hay AR, McNeal J, Freiha FS, and Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
10. Noldus J, and Stamey TA: Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. J Urol 155: 232-237, 1996.
11. Gleason DF, and the Veterans Administration Cooperative Urological Research Group: Histologic grading and staging of prostatic carcinoma, in Tannenbaum M (Ed): Urologic Pathology. Philadelphia, Lea & Febiger, 1977, pp 171-187.
12. Myrtle JF, Klimley PG, and Ivor LP: Clinical utility of prostate-specific antigen (PSA) in the management of prostate cancer, in Advances in Cancer Diagnostics, Hybritech Inc., 1986, Vol 1, No 1, pp 1-7.
13. Beahrs OH, Henson DE, and Hutter RVP: American Joint Committee on Cancer, Manual for Staging Cancer, 4th ed. Philadelphia, JP Lippincott, 1992.
14. D'Amico AV, and Propert K: Prostate cancer volume adds significantly to prostate specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys 35: 273-279, 1996.
15. Lepor H, Wang B, and Shapiro E: Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology 44: 199-205, 1994.
16. Marks LS, Treiger B, Dorey FJ, Fu YS, and DeKernion JB: Morphometry of the prostate: I. Distribution of tissue components in hyperplastic glands. Urology 44: 486-489, 1994.
17. Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, and Scardino PT: Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J Urol 151: 1558-1564, 1994.
18. Duncan RC, Knapp RG, and Miller MC III: Introductory Biostatistics for the Health Sciences. New York, John Wiley and Sons, 1983, pp 115-135.
19. Cox DR: Regression models and life tables. J R Stat Soc B 34: 187-195, 1972.
20. Benson MC, Whang IS, Olsson CA, McMahon DJ, and Cooner WH: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817-821, 1992.
21. Carter HB, Pearson JL, Metter J, Brant LJ, Chan DW, Andres R, Fozard JL, and Walsh PC: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
22. D'Amico AV, and Hanks GE: Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 72: 2638-2643, 1993.
23. Babaian RJ, Troncoso P, Steelhammer LC, Lloreta-Trull J, and Ramirez EI: Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. J Urol 154: 1808-1812, 1995.